Back

Effects of doxorubicin and ibrutinib on atrial arrhythmogenity: ex-vivo assessment in human myocardium

26 August 2022 (08:15 - 09:00)
Organised by:
Congress Presentation Part of: Arrhythmia mechanisms Pathophysiology and Mechanisms ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Mr Yannic Wanja Berger

Charité - University Medicine Berlin, Berlin (Germany)

6 More presentations in this session

Presentation thumbnail
The ideal environment for the development of postcardiac surgery atrial fibrillation: evidence for endothelial activation and poor cell-cell interaction.
Doctor R. Lopez-Galvez (Murcia, ES)
Abstract Slides
Presentation thumbnail
Pulmonary vein anatomical variants and incidence of atrial fibrillation
Doctor R. Gallen (Dublin, IE)
Abstract Slides
Presentation thumbnail
Identifying proteomic profiles as indicators of disease severity in arrhythmogenic cardiomyopathy
Doctor D. Akdis (Zurich, CH)
Abstract Slides
Presentation thumbnail
Immune status comparison in patients with atrial fibrillation or flutter on the base of arterial hypertension
Doctor O. Stasyshena (Kiev, UA)
Abstract Slides
Presentation thumbnail
"Concealed cardiomyopathy" is an important cause of autopsy-inconclusive sudden cardiac death and diagnosis impacts care of surviving relatives
Doctor J. Isbister (Sydney, AU)
Abstract Slides

Access the full session

Session thumbnail
Arrhythmia mechanisms

The Event

Event poster

ESC Congress 2022

26 August 2022 08:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources